Member Info for OAPK20

GG- Hope this helps

Without news on Monday

If momentum remains strong and there is follow-through buying, the price could open higher or continue rising after a slight pullback. Look for increased volume to confirm strength. After an 8% rise, some traders might take profits, leading to a minor pullback before resuming the uptrend.

Volume on Monday’s open – strong volume confirms continued buying interest. If the overall market is weak, GRL might struggle to sustain gains.

At 1.28p, key support and resistance levels are:

Accumulated Volume Support & Resistance Levels:

• Resistance Levels:

• R1: 1.30p (1.88% above current price)

• R2: 1.33p (4.31% above)

• R3: 1.35p (5.88% above)

• Support Levels:

• S1: 1.25p (1.96% below current price)

• S2: 1.08p (15.69% below)

• S3: 1.03p (19.61% below)

Pivot Point: 1.13p

Support Levels:

• S1: 1.10p

• S2: 1.02p

• S3: 0.98p

• Resistance Levels:

• R1: 1.21p

• R2: 1.25p

• R3: 1.33p

Moving Averages:

• 5-Day MA: 1.15p (Simple), 1.18p (Exponential) – Both indicate a ‘Buy’ signal.

• 10-Day MA: 1.10p (Simple), 1.14p (Exponential) – Both indicate a ‘Buy’ signal.

• 20-Day MA: 1.13p (Simple and Exponential) – Both indicate a ‘Buy’ signal.

• 50-Day MA: 1.17p (Simple), 1.14p (Exponential) – Both indicate a ‘Buy’ signal.

• 100-Day MA: 1.13p (Simple), 1.16p (Exponential) – Both indicate a ‘Buy’ signal.

• 200-Day MA: 1.14p (Simple), 1.28p (Exponential) – Both indicate a ‘Buy’ signal.

These moving averages suggest a bullish trend for GRL

GRL is currently exhibiting bullish signals, with key resistance levels at 1.34p and 1.39p, and support levels at 1.16p and 1.11p.

RNS 1000oz Gold pour though and it’s reassess, hopefully at much higher levels.

DYOR 😜

Hammer - Price went up.

"I think you really are an OAP. Have a sherry and stay warm."

Old soldiers are old for a reason.

Am I old though?

Bring on the news, bring the Gold.........

FDA approval can’t come soon enough.

GENinCode PLC’s Enterprise Value-to-Revenue (EV/Revenue) ratio of 4.3x requires context within the biotechnology sector.

Industry Averages:

• Biotechnology Sector:

• As of January 2025, the average EV/Revenue multiple is 20.20x.

In 2023, the median EV/Revenue multiple was 12.97x

Biotech & Genomics Companies:

• In Q4 2024, the median EV/Revenue multiple was 6.2x.

GENinCode’s EV/Revenue ratio of 4.3x is below these industry averages, suggesting a potential undervaluation. However, valuation depends on factors like growth prospects, profitability, and market conditions.

FDA Approval on the Horizon: The company is in the final stages of securing De Novo FDA approval for CARDIO inCode-Score, expected in Q2 2025.

Medicare Reimbursement: CMS has already included CARDIO inCode-Score in its 2025 Clinical Lab Fee Schedule, with a price of ~$500 per test, paving the way for broad U.S. insurance coverage.

Unlike traditional cholesterol and blood pressure tests, GENinCode’s technology assesses genetic predisposition to CVD, offering a more personalized risk assessment.

PRS-based tests are gaining traction, and GENinCode is among the first movers in this space, particularly in the U.S.

The company has collaborations with U.S. healthcare providers and insurers, setting the stage for rapid market penetration once regulatory approval is secured.

While FDA approval looks promising, delays or additional data requests could impact the timeline.

FDA approval in 2025 could trigger a significant stock price re-rating.

Successful commercialization in the U.S. could drive strong revenue growth and potential profitability.

GENinCode could become a key player in the genomic diagnostics market, making it a possible acquisition target for larger biotech firms.

“ GENinCode appears to be on track for FDA approval of CARDIO inCode-Score in the near future.”

Not Don. Different source.

Is it boom or bust here? Do they have sufficient capital to continue or are ZOO at this SP on their competitors radar?

Zoo Digital has made significant investments in technology to improve its workflows, particularly with AI and cloud-based systems. This can enhance its scalability, improve turnaround times, and drive cost efficiencies. Automation and AI-based tools could give Zoo a competitive edge and allow it to cater to more clients at a lower cost, driving growth.

Will Amazon Prime Video deal come off ?

Zoo Digital has been growing its client base, which includes some of the world's largest content creators and distributors. Expanding its roster of clients, particularly with big players in the entertainment and tech industries, could help the company increase revenue and strengthen its position in the market.

The global streaming market is growing rapidly, with companies like Netflix, Amazon Prime, Disney+, and others pushing for more localized content to cater to international audiences. As the demand for localized content (subtitles, dubbing, etc.) increases, Zoo Digital, which specializes in these services, stands to benefit. The company's core business model directly supports this growing trend.

The rise in global content consumption is pushing the need for companies like Zoo Digital that offer language and localization services. Zoo Digital helps its clients adapt content for various regions, which is crucial for reaching a diverse international audience. As more companies prioritize global expansion, the need for localization services will likely increase.

Zoo Digital operates in a competitive industry, where there are numerous players offering similar services (subtitling, dubbing, and localization). Competitors may offer lower prices, more advanced technology, or greater scalability, which could impact Zoo's market share.

Larger players might seek to acquire smaller companies like Zoo Digital to expand their capabilities.

.

On the chart. Good news = Breakout

Placing, dilution, flipping

Raised total of £1.57m through:

o a subscription for 36,000,000 new ordinary shares of 1p each in the Company at a price of 2.90p, and

o a £522,000 convertible loan note from the existing majority shareholder Foreign Dimensions PTY Limited, convertible at 2.90p per ordinary share

Sell this morning. As I said still not done

Still not done

Not done yet it seems

CLSK 2p should’ve been hit on record gold pour but jitters about consistency (along with selling by

Devonport Capital Limited) have depressed the SP.

The 6g/t layer is under 10m thick layer of overburden with is a lot of digging, a lot of trucking, a lot of man hours, and a lot of fuel.

GRL needs to CONFIRM consistent gold recovery and build up the war chest to fund getting down to higher grades.

It would help if they stick to one measurement instead of obfuscating gold recovery figures by switching between Gold dore, Kilos, ounces and Troy ounces.

Would help improve trust from investors.

That’s the point. They haven’t hit targets and the SP is behaving accordingly.

There are 2 strike points to hit before ASIC below $1500. They haven’t hit the first.

Too many people suggesting low ASIC of $1500 and lower.

Simply not true. IF they reach $1500 for 3 consecutive months at Homase OPTIONS kick in at 3p.

THEY HAVE’NT.

“A total of 56,000,000 Options have been granted, of which: 50% will vest immediately and are exercisable at a price of £0.02 per ordinary share ("Tranche 1"); 25% will vest when production is greater than 650 oz per month for three consecutive months and are exercisable at £0.025 per ordinary share ("Tranche 2"); and 25% will vest when all-in sustaining production costs at the Homase Mine are reduced to US$1,500 per month for three consecutive months and are exercisable at a price of £0.03 per ordinary share ("Tranche 3").”

AIC $1600/oz Ave 350oz p/m 4200oz AIC $6,720,000p/a

From GRL - AIC $870/oz Ave 1666oz p/m AIC $1,459,420p/a

Rational for $700k ?

Massively understated the costs.

Yes

Anyone interested.

“You will be responsible for carrying out patient testing within the London laboratory and the delivery of high quality Clinical Gentics services to both private and NHS patients”

Hopefully a sign of expansion and another NHS region onboarding. Be interesting to see.

Unless it’s just one for one replacement…..